LifeMD

LFMD

Market cap $187M

LifeMD expands its weight management program with the addition of Foundayo, offering eligible patients an oral alternative to injectable GLP-1 therapies through LillyDirect® LifeMD expands its weight management program with the addition of Foundayo, offering eligible patients an oral alternative to injectable GLP-1 therapies through LillyDirect®

Delivering up to $1,200 in annual patient savings on branded GLP-1 therapy, expanding LifeMD's collaboration with Novo Nordisk Delivering up to $1,200 in annual patient savings on branded GLP-1 therapy, expanding LifeMD's collaboration with Novo Nordisk

NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that its Board of Directors has authorized a cash dividend to holders of the Company's 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) equal to $0.5546875 per share.

NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced the appointment of Atul Kavthekar as Chief Financial Officer, effective today. The Company also announced leadership changes to support its next phase of growth.

LifeMD is rated Buy, trading at a low 0.796x TTM sales, with upside if multiples revert. LFMD's strategic divestment of WorkSimpli refocused the business as a pure-play telehealth and pharmacy provider. The recent launch of the Wegovy pill will expand growth from its GLP-1 vertical.

LifeMD, Inc. (LFMD) Q4 2025 Earnings Call Transcript

LifeMD, Inc. (LFMD) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to a loss of $0.02 per share a year ago.

Full year 2025 revenue grew 25% to $194.1 million; adjusted EBITDA rose 309% to $15.3 million. Fourth quarter revenue increased 4% to $46.9 million; adjusted EBITDA rose 348% to $4.8 million.

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that management will be participating in the following investor conferences during the month of March:

LifeMD remains a deeply undervalued telehealth stock, now trading with significant pessimism priced in after a 55% decline. LFMD's business model faces risks from slowing growth, legal issues, competition, and a disappointing WorkSimpli sale, but the fundamental story remains intact. Preferred shares yield just under 10% and offer lower risk, but I favor the common stock for its substantial upside potential at current prices.